Skip to main content
Erschienen in: Digestive Diseases and Sciences 4/2024

15.02.2024 | Original Article

Influence of Helicobacter pylori Infection and Eradication on Small Intestinal Bacterial Overgrowth and Abdominal Symptoms

verfasst von: Xiaolei Wang, Die Zhu, Siyu Li, Yun Dai, Guigen Teng, Weihong Wang

Erschienen in: Digestive Diseases and Sciences | Ausgabe 4/2024

Einloggen, um Zugang zu erhalten

Abstract

Background

The relationship between Helicobacter pylori (H. pylori) infection and small intestinal bacterial overgrowth (SIBO) has attracted attention recently.

Aims

To analyze the influence of H. pylori infection and eradication on SIBO, IMO, and abdominal symptoms.

Methods

Patients with gastrointestinal symptoms were tested for 13C urea breath test and if positive, treated with bismuth-based quadruple therapy. Lactulose hydrogen methane breath test (HMBT) was performed and symptoms were assessed using gastrointestinal symptom rating scale (GSRS) before and 6 weeks after eradication.

Results

Of the 102 subjects, 53 were H. pylori positive. The prevalence of SIBO and IMO were higher in patients with H. pylori infection than in those without infection (49.1% vs 24.5%, P = 0.019 for SIBO; 24.5% vs 8.2%, P = 0.027 for IMO). GSRS scores were similar between H. pylori-infected and uninfected patients (2 (IQR: 1;3) vs 2 (IQR: 1;2), P = 0.211). Patients with SIBO or IMO presented higher GSRS scores than patients with both SIBO and IMO negative (2 (IQR: 2;3), 2 (IQR: 2;3) vs 2 (IQR: 1;2), P = 0.011, 0.001, respectively). For the 50 patients who successfully eradicated H. pylori, the response rates for SIBO and IMO were 66.7% and 76.9%, respectively. GSRS scores also significantly decreased (2 (IQR: 1;3) to 0 (IQR: 0;1), P < 0.001) after eradication.

Conclusion

Helicobacter pylori infection was associated with higher prevalence of SIBO and IMO, both of which led to more pronounced abdominal symptoms. H. pylori eradication also achieved therapeutic effects on SIBO and IMO, accompanied by relief of abdominal symptoms.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Dore MP, Pes GM, Bassotti G, Usai-Satta P. Dyspepsia: when and how to test for Helicobacter pylori infection. Gastroenterol Res Pract 2016;2016:8463614.CrossRefPubMedPubMedCentral Dore MP, Pes GM, Bassotti G, Usai-Satta P. Dyspepsia: when and how to test for Helicobacter pylori infection. Gastroenterol Res Pract 2016;2016:8463614.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Ghoshal UC, Shukla R, Ghoshal U. Small intestinal bacterial overgrowth and irritable bowel syndrome: a bridge between functional organic dichotomy. Gut Liver 2017;11:196–208.CrossRefPubMedPubMedCentral Ghoshal UC, Shukla R, Ghoshal U. Small intestinal bacterial overgrowth and irritable bowel syndrome: a bridge between functional organic dichotomy. Gut Liver 2017;11:196–208.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Pimentel M, Saad RJ, Long MD, Rao SSC. ACG clinical guideline: small intestinal bacterial overgrowth. Am J Gastroenterol 2020;115:165–178.CrossRefPubMed Pimentel M, Saad RJ, Long MD, Rao SSC. ACG clinical guideline: small intestinal bacterial overgrowth. Am J Gastroenterol 2020;115:165–178.CrossRefPubMed
5.
Zurück zum Zitat Massey BT, Wald A. Small intestinal bacterial overgrowth syndrome: a guide for the appropriate use of breath testing. Dig Dis Sci 2021;66:338–347.CrossRefPubMed Massey BT, Wald A. Small intestinal bacterial overgrowth syndrome: a guide for the appropriate use of breath testing. Dig Dis Sci 2021;66:338–347.CrossRefPubMed
6.
Zurück zum Zitat Erdogan A, Rao SS, Gulley D et al. Small intestinal bacterial overgrowth: duodenal aspiration vs glucose breath test. Neurogastroenterol Motil 2015;27:481–489.CrossRefPubMed Erdogan A, Rao SS, Gulley D et al. Small intestinal bacterial overgrowth: duodenal aspiration vs glucose breath test. Neurogastroenterol Motil 2015;27:481–489.CrossRefPubMed
7.
Zurück zum Zitat Rezaie A, Buresi M, Lembo A et al. Hydrogen and methane-based breath testing in gastrointestinal disorders: the North American Consensus. Am J Gastroenterol 2017;112:775–784.CrossRefPubMedPubMedCentral Rezaie A, Buresi M, Lembo A et al. Hydrogen and methane-based breath testing in gastrointestinal disorders: the North American Consensus. Am J Gastroenterol 2017;112:775–784.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Cangemi DJ, Lacy BE, Wise J. Diagnosing small intestinal bacterial overgrowth: a comparison of lactulose breath tests to small bowel aspirates. Dig Dis Sci. 2021;66:2042–2050.CrossRefPubMed Cangemi DJ, Lacy BE, Wise J. Diagnosing small intestinal bacterial overgrowth: a comparison of lactulose breath tests to small bowel aspirates. Dig Dis Sci. 2021;66:2042–2050.CrossRefPubMed
9.
Zurück zum Zitat Enko D, Kriegshäuser G. Functional 13C-urea and glucose hydrogen/methane breath tests reveal significant association of small intestinal bacterial overgrowth in individuals with active Helicobacter pylori infection. Clin Biochem 2017;50:46–49.CrossRefPubMed Enko D, Kriegshäuser G. Functional 13C-urea and glucose hydrogen/methane breath tests reveal significant association of small intestinal bacterial overgrowth in individuals with active Helicobacter pylori infection. Clin Biochem 2017;50:46–49.CrossRefPubMed
10.
Zurück zum Zitat Del Zompo F, Ojetti V, Feliciani D et al. Helicobacter pylori infection is associated with high methane production during lactulose breath test. Eur Rev Med Pharmacol Sci 2016;20:3452–3456.PubMed Del Zompo F, Ojetti V, Feliciani D et al. Helicobacter pylori infection is associated with high methane production during lactulose breath test. Eur Rev Med Pharmacol Sci 2016;20:3452–3456.PubMed
11.
Zurück zum Zitat Zhou M, Wang AM, Wang JK, Jia SJ. Relationship between Helicobacter pylori related peptic ulcer and small intestinal bacterial overgrowth. Chin J Gastroenterol Hepatol 2013;22:60–61. Zhou M, Wang AM, Wang JK, Jia SJ. Relationship between Helicobacter pylori related peptic ulcer and small intestinal bacterial overgrowth. Chin J Gastroenterol Hepatol 2013;22:60–61.
12.
Zurück zum Zitat Liu WZ, Xie Y, Lu H et al. Chinese Society of Gastroenterology, Chinese Study Group on Helicobacter pylori and peptic ulcer. Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection. Helicobacter 2018;23:e12475.CrossRefPubMed Liu WZ, Xie Y, Lu H et al. Chinese Society of Gastroenterology, Chinese Study Group on Helicobacter pylori and peptic ulcer. Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection. Helicobacter 2018;23:e12475.CrossRefPubMed
13.
Zurück zum Zitat Su T, Lai S, Lee A, He X, Chen S. Meta-analysis: proton pump inhibitors moderately increase the risk of small intestinal bacterial overgrowth. J Gastroenterol 2018;53:27–36.CrossRefPubMed Su T, Lai S, Lee A, He X, Chen S. Meta-analysis: proton pump inhibitors moderately increase the risk of small intestinal bacterial overgrowth. J Gastroenterol 2018;53:27–36.CrossRefPubMed
15.
Zurück zum Zitat Smolka AJ, Schubert ML. Helicobacter pylori-induced changes in gastric acid secretion and upper gastrointestinal disease. Curr Top Microbiol Immunol 2017;400:227–252.PubMed Smolka AJ, Schubert ML. Helicobacter pylori-induced changes in gastric acid secretion and upper gastrointestinal disease. Curr Top Microbiol Immunol 2017;400:227–252.PubMed
16.
Zurück zum Zitat Dharan M, Wozny D. Helicobacter pylori infection and small intestinal bacterial overgrowth-more than what meets the eye. World J Clin Cases 2022;10:7209–7214.CrossRefPubMedPubMedCentral Dharan M, Wozny D. Helicobacter pylori infection and small intestinal bacterial overgrowth-more than what meets the eye. World J Clin Cases 2022;10:7209–7214.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Suzuki H, Moayyedi P. Helicobacter pylori infection in functional dyspepsia. Nat Rev Gastroenterol Hepatol 2013;10:168–174.CrossRefPubMed Suzuki H, Moayyedi P. Helicobacter pylori infection in functional dyspepsia. Nat Rev Gastroenterol Hepatol 2013;10:168–174.CrossRefPubMed
18.
Zurück zum Zitat Lopetuso LR, Scaldaferri F, Franceschi F, Gasbarrini A. The gastrointestinal microbiome-functional interference between stomach and intestine. Best Pract Res Clin Gastroenterol 2014;28:995–1002.CrossRefPubMed Lopetuso LR, Scaldaferri F, Franceschi F, Gasbarrini A. The gastrointestinal microbiome-functional interference between stomach and intestine. Best Pract Res Clin Gastroenterol 2014;28:995–1002.CrossRefPubMed
19.
Zurück zum Zitat Heimesaat MM, Fischer A, Plickert R et al. Helicobacter pylori induced gastric immunopathology is associated with distinct microbiota changes in the large intestines of long-term infected Mongolian gerbils. PLoS ONE 2014;9:e100362.CrossRefPubMedPubMedCentral Heimesaat MM, Fischer A, Plickert R et al. Helicobacter pylori induced gastric immunopathology is associated with distinct microbiota changes in the large intestines of long-term infected Mongolian gerbils. PLoS ONE 2014;9:e100362.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Gatta L, Scarpignato C. Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. Aliment Pharmacol Ther 2017;45:604–616.CrossRefPubMedPubMedCentral Gatta L, Scarpignato C. Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. Aliment Pharmacol Ther 2017;45:604–616.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Lauritano EC, Gabrielli M, Scarpellini E et al. Antibiotic therapy in small intestinal bacterial overgrowth: rifaximin versus metronidazole. Eur Rev Med Pharmacol Sci 2009;13:111–116.PubMed Lauritano EC, Gabrielli M, Scarpellini E et al. Antibiotic therapy in small intestinal bacterial overgrowth: rifaximin versus metronidazole. Eur Rev Med Pharmacol Sci 2009;13:111–116.PubMed
22.
Zurück zum Zitat Attar A, Flourié B, Rambaud JC et al. Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: a crossover, randomized trial. Gastroenterology 1999;117:794–797.CrossRefPubMed Attar A, Flourié B, Rambaud JC et al. Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: a crossover, randomized trial. Gastroenterology 1999;117:794–797.CrossRefPubMed
23.
Zurück zum Zitat Konrad P, Chojnacki J, Gąsiorowska A et al. Therapeutic efficacy of amoxicillin and rifaximin in patients with small intestinal bacterial overgrowth and Helicobacter pylori infection. Prz Gastroenterol 2018;13:213–217.PubMedPubMedCentral Konrad P, Chojnacki J, Gąsiorowska A et al. Therapeutic efficacy of amoxicillin and rifaximin in patients with small intestinal bacterial overgrowth and Helicobacter pylori infection. Prz Gastroenterol 2018;13:213–217.PubMedPubMedCentral
24.
Zurück zum Zitat Ford AC, Marwaha A, Sood R, Moayyedi P. Global prevalence of, and risk factors for, uninvestigated dyspepsia: a meta-analysis. Gut 2015;64:1049–1057.CrossRefPubMed Ford AC, Marwaha A, Sood R, Moayyedi P. Global prevalence of, and risk factors for, uninvestigated dyspepsia: a meta-analysis. Gut 2015;64:1049–1057.CrossRefPubMed
25.
Zurück zum Zitat Yazdanbod A, Salimian S, Habibzadeh S et al. Effect of Helicobacter pylori eradication in Iranian patients with functional dyspepsia: a prospective, randomized, placebo-controlled trial. Arch Med Sci 2015;11:964–969.PubMedPubMedCentral Yazdanbod A, Salimian S, Habibzadeh S et al. Effect of Helicobacter pylori eradication in Iranian patients with functional dyspepsia: a prospective, randomized, placebo-controlled trial. Arch Med Sci 2015;11:964–969.PubMedPubMedCentral
26.
Zurück zum Zitat Zhao W, Zhong X, Zhuang X et al. Evaluation of Helicobacter pylori eradication and drug therapy in patients with functional dyspepsia. Exp Ther Med 2013;6:37–44.CrossRefPubMedPubMedCentral Zhao W, Zhong X, Zhuang X et al. Evaluation of Helicobacter pylori eradication and drug therapy in patients with functional dyspepsia. Exp Ther Med 2013;6:37–44.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Sodhi JS, Javid G, Zargar SA et al. Prevalence of Helicobacter pylori infection and the effect of its eradication on symptoms of functional dyspepsia in Kashmir, India. J Gastroenterol Hepatol 2013;28:808–813.CrossRefPubMed Sodhi JS, Javid G, Zargar SA et al. Prevalence of Helicobacter pylori infection and the effect of its eradication on symptoms of functional dyspepsia in Kashmir, India. J Gastroenterol Hepatol 2013;28:808–813.CrossRefPubMed
29.
Zurück zum Zitat Tan VP, Liu KS, Lam FY et al. Randomised clinical trial: rifaximin versus placebo for the treatment of functional dyspepsia. Aliment Pharmacol Ther 2017;45:767–776.CrossRefPubMed Tan VP, Liu KS, Lam FY et al. Randomised clinical trial: rifaximin versus placebo for the treatment of functional dyspepsia. Aliment Pharmacol Ther 2017;45:767–776.CrossRefPubMed
30.
Zurück zum Zitat Lauritano EC, Gabrielli M, Scarpellini E et al. Small intestinal bacterial overgrowth recurrence after antibiotic therapy. Am J Gastroenterol 2008;103:2031–2035.CrossRefPubMed Lauritano EC, Gabrielli M, Scarpellini E et al. Small intestinal bacterial overgrowth recurrence after antibiotic therapy. Am J Gastroenterol 2008;103:2031–2035.CrossRefPubMed
Metadaten
Titel
Influence of Helicobacter pylori Infection and Eradication on Small Intestinal Bacterial Overgrowth and Abdominal Symptoms
verfasst von
Xiaolei Wang
Die Zhu
Siyu Li
Yun Dai
Guigen Teng
Weihong Wang
Publikationsdatum
15.02.2024
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 4/2024
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-024-08279-y

Weitere Artikel der Ausgabe 4/2024

Digestive Diseases and Sciences 4/2024 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

11.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Im Battle of Experts traten zwei Experten auf dem Diabeteskongress gegeneinander an: Die eine vertrat die Auffassung „Sport statt Spritze“ bei Adipositas und Typ-2-Diabetes, der andere forderte „Spritze statt Sport!“ Am Ende waren sie sich aber einig: Die Kombination aus beidem erzielt die besten Ergebnisse.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.